Union Bancaire Privee Boosts Regeneron Pharmaceuticals Stake

Institutional investor increases holding in biotech company by over 600%

Mar. 21, 2026 at 11:44am

Got story updates? Submit your updates here. ›

Union Bancaire Privee UBP SA, a Swiss private banking group, significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 672.3% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 3,993 shares of the biopharmaceutical company's stock, valued at $3,019,000.

Why it matters

Regeneron Pharmaceuticals is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. The increase in ownership by a major institutional investor like Union Bancaire Privee suggests confidence in the company's long-term growth potential.

The details

According to the SEC filing, Union Bancaire Privee UBP SA acquired an additional 3,476 shares of Regeneron Pharmaceuticals during the fourth quarter, bringing its total position to 3,993 shares. This represents a significant increase of 672.3% compared to the firm's previous holdings in the company.

  • Union Bancaire Privee UBP SA increased its Regeneron Pharmaceuticals stake in the fourth quarter of 2025.

The players

Union Bancaire Privee UBP SA

A Swiss private banking group that has increased its stake in Regeneron Pharmaceuticals by over 600%.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in ownership by Union Bancaire Privee UBP SA suggests that the institutional investor sees strong growth potential in Regeneron Pharmaceuticals' innovative drug pipeline and technology platform. This move highlights the biotech firm's appeal to major investors in the healthcare sector.